Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.37 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | CCR8 | P51685 | 1/20 | 0.36 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5640712 | 0.83 | — | — | |
| Ammonia Solution, Strong SCHEMBL1845719 | 0.81 | NOS3 (0.46) | NOS3NOS1NOS2ALDH1A1NPC1 | |
| SCHEMBL245136 | 0.81 | — | — | |
| SCHEMBL7615368 | 0.81 | — | — | |
| SCHEMBL27013272 | 0.81 | — | — | |
| SCHEMBL14218666 | 0.81 | — | — | |
| SCHEMBL13402386 | 0.79 | GABRA1 (0.35) | NOS3NOS1NOS2ALDH1A1TSHR | |
| SCHEMBL19041910 | 0.79 | ALDH1A1 (0.37) | NOS3NOS1NOS2ALDH1A1NPC1 | |
| SCHEMBL12048608 | 0.78 | KDM4E (0.45) | NOS3NOS1NOS2ALDH1A1NPC1 | |
| SCHEMBL1583838 | 0.78 | NOS3 (0.43) | NOS3NOS1NOS2ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070027310-A1 | Novel ligands and methods for preparing same | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2007-02-01 | — | — | US | claimed |
| US-20040132981-A1 | Novel ligands and methods for preparing same | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2004-07-08 | — | — | US | claimed |
| CN-1418111-A | Novel Ligands and method for preparing same | NAT UNIV SINGAPORE (SG) | 2003-05-14 | — | — | CN | claimed |
| EP-1289561-A2 | LIGAND CONJUGATES AND METHODS FOR PREPARING SAME | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2003-03-12 | — | — | EP | claimed |
| US-20010051348-A1 | Novel ligands and methods for preparing same | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2001-12-13 | — | — | US | claimed |
| WO-2001054731-A2 | LIGAND CONJUGATES AND METHODS FOR PREPARING SAME | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2001-08-02 | — | — | WO | claimed |
| CN-119455003-A | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119455004-A | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-113660957-B | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-118786140-A | Anti-SARS-CoV-2 spike (S) antibodies and their use in treatment COVID-19 | 诺瓦瓦克斯股份有限公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-117440833-A | anti-HER 2 antibody-drug conjugates and uses thereof | AMBRX公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-109313200-B | Bioanalytical methods for characterizing site-specific antibody-drug conjugates | 豪夫迈·罗氏有限公司 | 2022-10-04 | — | — | CN | disclosed |
| CN-109071657-B | Pharmaceutical compositions comprising bispecific antibody constructs | 安进研发（慕尼黑）股份有限公司 | 2022-05-31 | — | — | CN | disclosed |
| WO-1999066030-A9 | DAP-KINASE RELATED PROTEIN | YEDA RES & DEV (IL) | 2000-07-06 | — | — | WO | disclosed |
| EP-1016414-A2 | Human growth hormone to stimulate hematopoiesis and immune reconstitution after hematopoietic stem cell transplantation in humans | Applied Research Systems ARS Holding N.V. (AN) | 2000-07-05 | — | — | EP | disclosed |
| EP-1016413-A1 | Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells | Applied Research Systems ARS Holding N.V. (AN) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999066030-A1 | DAP-KINASE RELATED PROTEIN | YEDA RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) | 1999-12-23 | — | — | WO | disclosed |
| CN-1137826-A | Method and compositions for treatment of BCR-ABL associated leukemias and other cell proliferative disorders | NEW YORK UNIV MEDICAL CENTER (US) | 1996-12-11 | — | — | CN | disclosed |
| CN-1047340-A | Therapeutical agent | BOOTS CO PLC (GB) | 1990-11-28 | — | — | CN | disclosed |
| US-4009168-A | STABILIZERS FOR POLYOLEFINS | UBE INDUSTRIES, LTD. (JA) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051348-A1 | Novel ligands and methods for preparing same | ADGRF1, ADGRE5, TACR2 | NOS3 4662/4885NOS1 4696/4885NOS2 4655/4885 |
| US-20070027310-A1 | Novel ligands and methods for preparing same | ADGRF1, ADGRE5, TACR2 | NOS3 4662/4885NOS1 4696/4885NOS2 4655/4885 |
| US-20040132981-A1 | Novel ligands and methods for preparing same | ADGRF1, ADGRE5, TACR2 | NOS3 4662/4885NOS1 4696/4885NOS2 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.